Chemistry Diversity
KareBayTM Biochem is technically advanced in chemistry diversity. Experienced chemists here construct peptides with special amino acids and multiple modifications, and even developed patent substrates conjugated on peptide to help on dynamic studies in biological processes. Going through our introduction, and explore your modification or substrates in the list.
KareBay can offer variety of modifications, including fluorophores, fluorescent dye loaded nanoparticles., Isotope labels, MAPS and Carrier Complex, N-Methyl amino acids, unusual amino acids, phosphorylation, glycosylation, O-sulfonation, cyclic peptides, peptide mimetics, etc. These modifications can be classified into several categories in below table, and one can click to see more details for each category:
Table of modifications: Click to explore
N terminus Modification | Homo amino acid |
{H-},Free amino group | {Har}, HomoArg |
{Ac},Acetylation | {HPh}, HomoPhe |
{Br-Ac},Bromoacetyl | {D-HPh}, D-HomoPhe |
{Bromopropionyl} | {Hse}, HomoSer |
{Cl-Ac},Chloroacetyl | {D-Hse}, D-HomoSer |
{Fmoc},9-Fluorenylmethyloxycarbonyl | {HomoCit}, HomoCit |
{CBZ},Benzyloxycarbonyl | {D-HomoCit}, D-HomoCit |
{Bz},benzoyl | {HomoLeu}, HomoLeu |
{Boc},tertbutoxycarbonyl | {HomoPro}, HomoPro |
{But}, Butyric acid | {D-HomoPro}, D-HomoPro |
{Suc},succinyl | {beta-HomoIle}, beta-HomoIle |
{Allyl},allyl | {beta-HomoLeu}, beta-HomoLeu |
{Acryl},acryl | {beta-HomoMet}, beta-HomoMet |
{Alloc},allyloxycarbonyl | {beta-HomoPro}, beta-HomoPro |
{For}, Formylation | {beta-HomoTyr}, beta-HomoTyr |
{HPP},4-Hydroxyphenylpropionic acid | Isotope label |
{pGlu},{Pyr},Pyroglutamyl | N15 Ala |
{LA}, Lipoic acid | N15 Gly |
{Mpa},3-Mercaptopropyl | N15 Val |
{6-mercaptohexanoic acid} | N15 Pro |
{Mal}, Maleimide, Maleoyl-?-Ala | N15 Leu |
Nitrilotriacetyl | N15 Ile |
{mPEG2000}, {mPEG3000}, {mPEG5000}, Mal-PEG12 | N15 Phe |
{Hex}, Hexanoic acid | N15 Asp |
{Oct}, Octanoic acid | N15 Thr |
{Dec}, Decanoic acid | N15 Glu |
{Pal}, Palmitic acid | N15 Lys |
{Ste}, Stearic acid | N15 Tyr |
{Myr}, Myristic acid | N15 Arg |
{Lau}, Lauric acid | N15 Gln |
{Ahx}, aminohexanoic acid | Others |
{Lipid} (with two hydrophobic tails) | Quenched fluorescent peptide |
{Cy dyes} Cy3, Cy5, Cy5.5, Cy7 | Abz/ Tyr (3-NO2) |
{Alexa dyes},AF350, 405, 430, 488, 514, 532, 546, 568, 594, 610, 647, 750, 790 | Abz |
{DyLight dyes} DY-415, 505, 550, 610, 615, 630, 631, 632, 650, 651, 652, 675, 676, 677, 678, 680, 681, 682, 700, 701, 731, 751, 776 and equivalents | Tyr (3-NO2) |
{Atto dyes} 390, 425, 465, 488, 495, 514, 520, 532, 565, 590, 610 | Glu(EDANS)-NH2 |
{Other dyes} | DABCYL |
{PNA} (Peptide nucleic acid) | DABCYL/Glu(EDANS)-NH2 |
{Other contrast labeling moiety, please specify } | Multiple Antigen Proteins (MAPs) and Carrier Proteins, MAPS and Carrier Complex |
{Drug molecule, please specify} | Asymmetric 2 Branches (Pure) |
{Microspheres} | Orn Symmetric 2 Branches (Pure) |
{Nanoparticles} | Asymmetric 4 Branches (Crude) |
Carrier proteins (KHL, BSA, OVA) | Orn Symmetric 4 Branches (Crude) |
C terminus Modification | Asym metric 8 Branches (Crude) |
{-OH}, free acid group | Orn Symmetric 8 Branches (Crude) |
{NH2}, Amidation | Glu 2 Branches (N temrinus) |
{-CHO}, peptide aldehydes | Glycerol 3 branches (C terminus) |
{-OL}, alcohol peptide | n-mer Branch peptide on Lys side chain |
{CMK}, chloromethylketone | n-mer Branch peptide on Thr side chain |
{FMK}, Fluoromethylketone | n-mer Branch peptide on Ser side chain |
{Cya}, Cysteamide | BSA-Peptide N terminus |
{pNA},p-nitroaniline | BSA-Peptide C terminus |
{-pNP}, para-nitrophenol | BSA-Peptide Cys |
{AMC},7-Amino-4-methylcoumarin | KLH-Peptide N terminus |
{AFC} | KLH-Peptide C terminus |
-OMe (C-terminal) | KLH-Peptide Cys |
-OEt (C-terminal) | OVA-Peptide N terminus |
-OBzl (C-terminal) | OVA-Peptide C terminus |
-OtBu (C-terminal) | OVA-Peptide Cys |
{-OSu}, hydroxysucinimide ester | Spacers and Linkers |
-NHMe (C-terminal) | {Gly}, 2 Carbons |
-NHEt (C-terminal) | {Beta-Ala}, 3 Carbons |
-NHisopen (C-terminal) | {GABA}, 4 Carbons |
D form normal amino acid | {Ava}, 5 Carbons |
{D-Ala} | {Ahx}, 6 Carbons |
{D-Arg} | {AEA},Aminoethoxyacetic Acid |
{D-Asp} | {Mini-PEG}, 9 Carbons |
{D-Asn} | {Mini-PEG2}, 13 Carbons |
{D-Cys} | {Mini-PEG3}, 16 Carbons |
{D-Glu} | {ANP Linker} |
{D-Gln} | {other Linker, please specify} |
{D-His} | N-Methyl amino acids |
{D-Allo-Ile} | {Arg(Me)} |
{D-Leu} | {ADMA},{Arg(Me)2} asymmetrical |
{D-Lys} | {SDMA},{Arg(Me)2} symmetrical |
{D-Met} | {Tyr(Me)} |
{D-Pro} | {Thr(Me)} |
{D-Phe} | {Ser(Me)} |
{D-Ser} | {Cys(Me)}, SMC |
{D-Tyr} | {Lys(Me)} |
{D-Thr} | {Lys(Me2)} |
{D-Trp} | {Lys(Me3)} |
{D-Val} | {L-1-Me-Trp} |
Fluorescence/Dye Labeling | {L-2-Me-Trp} |
Biotin (N-Terminal) | {D-2-Me-Trp} |
Biotin-LC (N-Terminal) | {Tyr(Me)} |
Lys(Biotin) (middle) | {Tyr(Et)} |
Lys(Biotin) (C temrinus) | {D-Tyr(Et)} |
Lys(Biotin) (N terminus) | {Orn(Me)3} |
EDBiotin (C terminus) | {N-Me-Gly} |
FITC (N-Terminal) | {N-Me-Ser} |
FITC-LC (N-Terminal) | {N-Me-Tyr} |
Lys(FITC) (middle) | {N-Me-Thr} |
Lys(FITC) (C temrinus) | {N-Me-Asp} |
Lys(FITC) (N terminus) | {N-Me-Glu} |
EDFITC (C temrinus) | {N-Me-Ala} |
5-FAM (N-Terminal) | {N-Me-Phe} |
5-FAM-LC (N-Terminal) | {N-Me-Leu} |
Lys(5-FAM) (middle) | {N-Me-Ile} |
Lys(5-FAM) (C temrinus) | {N-Me-Val} |
Lys(5-FAM) (N-Terminus) | {N-Me-Met} |
ED5-FAM (C temrinus) | {N-Me-Nle} |
Dansyl (N-Terminal) | {N-Me-Nva} |
Dansyl-LC (N-Terminal) | Acetyl amino acids |
Lys(Dansyl) (middle) | {Lys(Ac)} |
Lys(Dansyl) (C temrinus) | Usual amino acids |
Lys(Dansyl) (N-Terminus) | {Catalog#} |
EDDansyl (C temrinus) | {Custom synthesis} |
TAMRA (N-Terminal) | Phosphorylation |
TAMRA-LC (N-Terminal) | {pSer},{D-pSer}, |
Lys(TAMRA) (middle) | {pTyr}, {D-pTyr}, |
Lys(TAMRA) (C temrinus) | {pThr}, {D-pThr} |
Lys(TAMRA) (N-terminus) | Glycosylation (such as Mannosylation) |
EDTAMRA (C temrinus) | {pSer},{D-pSer}, |
Lys(Dnp) (middle) | {pTyr}, {D-pTyr}, |
D-Lys(Dnp) (middle) | {pThr}, {D-pThr} |
Dab(Dnp) (middle) | O-Sulfonation |
Dap(Dnp) (middle) | {pSer},{D-pSer}, |
EDDnp (C terminus) | {pTyr}, {D-pTyr}, |
MCA (N-Terminal) | {pThr}, {D-pThr} |
Lys(MCA) (middle) | Cyclic Peptides |
Lys(MCA) (C temrinus) | Amide Cyclic Peptide(Head to Tail) |
Lys(MCA) (N-terminus) | Amide Cyclic Peptide(Side Chain) |
{D-4-NH2-Phe} | Orn Side Chain Amide Cyclic Peptide |
{L-4-NH2-Phe} | One Disulfide Bond |
{D-3-Cl-Tyr} | Two Disulfide Bonds |
{L-3-Cl-Tyr} | Three Disulfide Bonds |
{D-3,5-DiCl-Tyr} | Other Modifications and Free Services |
{L-3,5-DiCl-Tyr} | Up to 10 Free Aliquots (Why Aliquot?) |
{D-3,5-DiBr-Tyr} | Free HPLC Data |
{L-3,5-DiBr-Tyr} | Free MS Data |
{D-3-I-Tyr} | Free Certificate Of Analysis (COA) |
{L-3-I-Tyr} | Convert from TFA Salt to Acetate Salt or Hydrochloride Salt |
{D-3,5-DiI-Tyr} | Amino Acid Analysis |
{L-3,5-DiI-Tyr} | %N, Elemental Analysis |
{D-3-NO2-Tyr} | Solubility Test |
{L-3-NO2-Tyr} | Bioburden |
{D-3,5-DiNO2-Tyr} | Water Content |
{L-3,5-DiNO2-Tyr} | Bacterial Endotoxins |
Enzyme Substrates
KareBay is capable of three type of protease Fluorogenic/Iumogenic Peptide Substrates:(explore our full modifications list in DownLoad List.)
FRET based substrates
KareBay is one of the industry leaders in developing and providing fluorescence resonance energy transfer (FRET) and time resolved FRET (TR-FRET) peptide substrate for HTS assay to pharmaceutical and biotechnology companies. KareBay can provide Standard FRET dye pairs: Click to explore
Quencher
|
Fluorophore
|
Excitation(nm)
|
Emission (nm)
|
Dabcyl
|
Edans
|
340
|
490
|
Dansyl
|
Trp
|
336
|
350
|
DNP
|
Trp
|
328
|
393
|
DNP
|
MCA or Abz
|
328
|
420
|
Tyr (NO2)
|
Abz
|
320
|
490
|
Dnp
|
Mca
|
380
|
460
|
TQ2
|
5-FAM
|
490
|
520
|
TQ3 or QSY-7
|
5-TAMRA
|
547
|
574
|
TQ3 QSY-7
|
Eu(III) chelate
|
340
|
613
|
KareBay has experience with a wide range of protease peptide substrates, as show in the table below : Click to explore
Aggrecanase | CMV protease | Pepsin |
ADAMs | ECE-1 | Plasmin |
ACE-2 | Factor Xa | Plasmepsin II |
APCE | Furin | Proteinases |
2A protease | Granzyme K | Protein Tyrosin Phosphatase |
BACE1 | HCV protease | Renin |
Calpains | HIV protease | SARS |
Capases | HRV1 | TACE |
Carboxypeptidases | h Kallikreins | Thrombin |
Caspases | Interferon alpha A | TEV protease |
Cathepsins | Lethal Factor Protease | Trypsin |
Chymopapain | Malaria Aspartyl Proteinase | West Nile Virus Protease |
Complement component C1s | MMPs |
The design and synthesis work in KareBay for FRET and TR-FRET peptide substrates include modification of sequences, selection of donor/quencher pairs, improvement of FRET substrate solubility and quenching efficiency.
C-terminal modified substrates
For the C-terminal modified substrates, KareBay can offer a broad choice, including CMK, FMK, pNA, CHO, AMC, Rhodamine 110, Luciferin (lumonogenic), etc. Below table summarizes KareBay’s C-terminal modified substrates library: Click to explore
P1-(AA)n-X
|
Enzyme
|
P1-(AA)n-X
|
Enzyme
|
Z-DEVD-X | caspases-3 and -7 | Z-IEPD-X | granzyme B |
Z-LETD-X | caspase-8 | Z-IETD-X | granzyme B and caspase-6 |
GP-X | dipeptidyl peptidase 4 (DPPIV) | Z-TSAVLQ-X | SARS protease |
Z-LEHD-X | caspase-9 | Z-VNSTLQ-X | SARS protease |
Suc-LLVY-X | calpain- and chymotrypsin-like activities of proteasome | Z-FR-X | cathepsins B/L |
Z-LRR-X | trypsin-like activity of proteasome | Boc-VPR-X | kallikrein or thrombin |
Z-nLPnLD-X | caspase-like activity of proteasome | Z-GGR-X | thrombin |
Z-QEVY-X | calpain and proteasome chymotrypsin-like activity | Z-LR-X | Cathepsin K |
VP-X | dipeptidyl peptidase 4 (DPPIV) | Z-AAF-X | aminopeptidase |
Z-VDVAD-X | caspase-2 | Suc-AAPF-X | serine aminopeptidase |
Z-VEID-X | caspase-6 | Z-PRNK-X | tryptase |
Z-ATAD-X | caspase-12 | Z-RR-X | Cathepsin B |
Z-VAD-X | All Caspase | Z-YVAD-X | caspase-1 |
Z-AEVD-X | caspase-10 | Z-PHE-X | Serine Protease |
Z-LEU-X | Serine Protease | Z-LR-X | Cathepsin K |
Z-FR-X | Cathepsin L | Ac-Lys(Ac)-X | HDACs, Sirtuins |
Ac-K-X | Trypsin |
Self-quenched substrates (Silica-Cored Carrier Particle, US20090098057, US20090169482)
Protease peptide substrates labeled with self-quenching labile dyes, such as Cy7, are conjugated to a nanocarrier with such a high intensity that the dye molecules cause self-quenching among their vicinity neighbors. Enzyme cleavage of the peptide substrate releases the dye carrying fragment from nanoparticle surface into solution space, the self-quenching effect is released and the dye fluorescence intensity is recovered. This type of substrate can be used for cancer in-vivo imaging due to the nanoparticles beneficiary from EPR effect.(1) Principle illustration
Illustration of two pathways utilized to construct activatable probes using polymer-grafted silicon nanoparticle as the platform. A) Self-quenching strategy. With a couple of peptide-dye conjugates loaded onto one nanoparticle, the distance between those fluorophores are too far to induce self-quenching (a); however, with the increasing of peptide-dye conjugation density, the fluorophore starts to quench each other (b) and finally arrive` at a maximum quenched status (c); upon MMP-2 enzyme cleavage of the peptide linker, the fluorophores along with peptide fragment are released into the solution space, leading to a dequenching state (d). B) FRET strategy. Fluorophores are attached to the nanoparticle via peptide linker, while quenchers are directly attached to the nanoparticles, absorbing partial of the emission by the fluorophores. After enzymatic cleavage of the peptide linker, fluorphores along with peptide fragments are released into solution
Example, MMP2 peptide substrate labeled with Cy7:
Cy7-AhxPLG-VRGEE
Enzymatic assay results peptide substrate design: MMP2 peptide substrate labeled with Cy7: Effects of peptide density on signal amplification capability of nanoprobes. A) Nanoprobe signal amplification rate is tightly related to peptide-dye conjugate density on nanopartcile surface. With the increase percentage of reacted amine (with peptide-dye conjugates) on nanoparticle surface, nanoprobe signal amplification capability increases and achieves a maximum value at 62.8% of reacted amine; beyond this, such as for a 66.4% of reacted amine case, the amplification capability decreases instead.
96 plate-well analysis of activatable probe with various surface amine conjugated. Nanoparticle solutions are all of 100 ml, but with different concentration: Row 1: 1.08mg/ml, row 2: 0.0108 mg/ml, row 3: 0.0108 mg/ml in the presence of 0.2 mg MMP2 enzyme.
Detection of Matrix Metalloproteinase-2 (MMP2) activity in Breast cancer MCF-7 cells (A and B) with Fluorescence Image and NIR imaging. (A and C). Cy7 is attached to silicon nanoparticle (A, C) and to Peptide-dye conjugate loaded nanoparticle (B, D).
Switch to DownLoad List to find specific flyer on Self-squenched Substrates
Special Amino Acids
Name | CAS. NO. | Molecular Weight | Formula |
H-Pyr-oh | 98-79-3 | 129.1 | C5H7NO3 |
Boc-Pyr-OH | 53100-44-0 | 229.23 | C10H15NO5 |
Z-Pyr-OH | 32159-21-0 | 263.2 | C13H13NO5 |
3,5-Dinitro-Tyr-OH | 17360-11-1 | 289.2 | C9H11N3O8 |
H-Abu-OH | 1492-24-6 | 103.1 | C4H9NO2 |
Boc-Abu-OH.DCHA | 34306-42-8(net) | 384.5 | C9H17NO4.C12H23N |
Z-Abu-OH | 42918-86-5 | 237.3 | C12H15NO4 |
H-D-Abu-OH | 2623-91-8 | 103.1 | C4H9NO2 |
Fmoc-D-Abu-OH | 170642-27-0 | 325.4 | C19H19NO4 |
Fmoc-2-Abz-OH | 150256-42-1 | 359.4 | C22H17NO4 |
Boc-e-Acp-OH | 6404-29-1 | 231.3 | C11H21NO4 |
Fmoc-e-Acp-OH | 88574-06-5 | 353.3 | C21H23NO4 |
H-Aib-OH | 62-57-7 | 103.12 | C4H9NO2 |
Download List
How to get started Please contact us with your requests at service@karebaybio.com and we will reply with a detailed quote as soon as possible. This process usually takes between 24 and 48 hours and the quote will include an estimated price as well as the time required to complete the project. All inquiries and subsequent projects are handled in strict confidence and will be backed by a confidentiality agreement if desired.